An mRNA treatment for CF has been patented [166], providing an CFTR mRNA encapsulated in lipid nanoparticles that can increase the expression level and/or activity of CFTR in subjects, thus reducing the production of toxic metabolites associated with CFTR deficiency and/or dysfunction [166]. The gene discussed is CFTR; the disease is cystic fibrosis.